Copertina

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
di: Vincent Haghnejad, et al.
Pubblicazione: (2025)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Clearance of Hepatitis C Viremia During Direct‐Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism
di: Zahra Sarrafan‐Chaharsoughi, et al.
Pubblicazione: (2025)

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
di: Landon Long Chan, et al.
Pubblicazione: (2025)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
di: Supachaya Sriphoosanaphan, et al.
Pubblicazione: (2025)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
di: Jia‐Ling Wu, et al.
Pubblicazione: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
di: William Chai, et al.
Pubblicazione: (2025)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
di: Matheus Souza, et al.
Pubblicazione: (2026)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
di: Shuai Xia, et al.
Pubblicazione: (2025)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
di: Jimmy Che‐To Lai, et al.
Pubblicazione: (2026)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
di: Mary Yue Wang, et al.
Pubblicazione: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
di: Yu Shi, et al.
Pubblicazione: (2025)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Zhanbo Qu
Pubblicazione: (2026)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
di: Eduardo Vilar‐Gomez, et al.
Pubblicazione: (2025)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
di: Sai Kiran Kuchana, et al.
Pubblicazione: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
di: Jialing Wang, et al.
Pubblicazione: (2025)

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions
di: Julian Pohl, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study
di: Dhruv Ahuja, et al.
Pubblicazione: (2025)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
di: Takao Miwa, et al.
Pubblicazione: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
di: Luis Calzadilla Bertot, et al.
Pubblicazione: (2025)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)

Very Early‐Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma
di: Thomas Hunold, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
di: Mohammad Saeid Rezaee‐Zavareh, et al.
Pubblicazione: (2026)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Lauren Holtslander, et al.
Pubblicazione: (2025)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
di: Nina Kimer, et al.
Pubblicazione: (2024)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
di: Thanawin Pramotedham, et al.
Pubblicazione: (2026)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
di: Deliang Huang, et al.
Pubblicazione: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)